CrystecPharma to help develop inhaled formulation for respiratory conditions
SignalRx's SF2523 is a novel, small molecule dual PI3K-BRD4 inhibitor with a synergistic action on two pathways associated with the development of lung cancer and idiopathic pulmonary fibrosis
Breaking News
BD glass syringes capable of storage at deep cold temperatures
An analysis of approximately 2000 syringes showed no negative impact on key product functions when stored at -20°C and ...
Almac and Queen’s University Belfast collaboration passes midpoint
The KTP project has achieved multiple successful outcomes including dissemination through peer-reviewed publication and ...
Boehringer Ingelheim and OBT advance oncology candidate
The Boehringer Ingelheim drug candidate was discovered in a partnership with Oxford BioTherapeutics and enabled by ...
Delivering fixed-dose combination therapies with hard capsules: part I
In this article, authors Dr Jnanadeva Bhat and Ms Anita Solanki describe how fixed-dose combination therapies can be ...
Hookipa announces clinical collaboration with Merck USA
The collaboration will evaluate the combination of Hookipa’s arenaviral immunotherapeutic, and Merck’s Keytruda as ...
CytoSMART reopens research grant applications for Autumn
Through the grant, applicants can apply for either a Lux2, Lux3 FL, or an Omni live-cell imaging microscope, which they ...
Manufacturing vaccines, digital twins and lessons learned: part I
Using a digital replica of the manufacturing process, the pharmaceutical industry is exploring the ability of virtual ...
CPI launches RNA Centre of Excellence
To prepare for global demand for the technology, CPI is expanding capacity at its site in Darlington to include GMP ...
PharmaLex to join interdisciplinary vaccine initiative
The PharmaLex team will contribute to develop and qualify mathematical and statistical models that will be made ...
Developing optimised formulations with minimal drug substance
Advances in in silico and experimental techniques mean that APIs and prototype formulations can be thoroughly ...
Using ddPCR to accurately quantify AAV viral titre and integrity
Gene therapy is primed to become the next major development in medicine and bring relief to patients living with ...
Convenient magnesium supplementation: putting patients and consumers first
Martin Koeberle and Verena Garsuch of HERMES PHARMA explore how the application of specific formulation expertise and ...
Aptamer and Bio-Works collaborate on gene therapy scale up project
Under the agreement, Aptamer will develop an Optimer ligand capable of binding and eluting of a viral vector
Yposkesi joins BioPhorum CGT consortium
Key challenges facing biopharmaceutical manufacturers include ensuring production efficiency while operating in a ...
In Brief
Most Popular in Research
- PM David Cameron opens e-Therapeutics’ drug discovery centre
- Delivering fixed-dose combination therapies with hard capsules: part I
- Parenteral preparations: formulation challenges
- Immunotherapy: antibody drug conjugates from a small molecule perspective
- Particle size reduction strategies to improve drug performance
Featured Companies
Reports
